协和医学杂志

2017, v.8(Z2) 207-209

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的关键问题:再读共识
The Crucial Problems in the Treatment of Crohn's Disease with Anti-tumor Necrosis Factor-α Monoclonal Antibody

曹倩;
CAO Qian;IBD Center,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University;

摘要(Abstract):

炎症性肠病是一组病因尚不十分明确的慢性非特异性肠道炎症性疾病,包括溃疡性结肠炎和克罗恩病,以抗肿瘤坏死因子α单克隆抗体为代表的生物制剂在炎症性肠病中主要用于治疗克罗恩病。《抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)》在本期发布,通过再读新版共识,重点探讨抗肿瘤坏死因子α单克隆抗体治疗克罗恩病的部分关键问题,以帮助临床医生提高认识。
Inflammatory bowel diseases,including ulcerative colitis and Crohn's disease,are chronic nonspecific inflammatory diseases of bowels whose etiology is not clear. Anti-tumor necrosis factor( TNF)-α monoclonal antibody is one of the representative biological agents used for the treatment of Crohn's disease. The "2017revised Consensus on the Anti-TNF-α Monoclonal Antibody Therapy of Inflammatory Bowel Disease"will be published in current issue. From reviewing the new consensus,the author discussed some key points of anti-TNF-αmonoclonal antibody therapy in Crohn's disease,hoping to improve clinical practice of anti-TNF-α monoclonal antibody therapy in Crohn's disease.

关键词(KeyWords): 抗肿瘤坏死因子α单克隆抗体;克罗恩病
anti-tumor necrosis factor-α monoclonal antibody;Crohn's disease

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 曹倩;
CAO Qian;IBD Center,Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University;

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享